Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy

Johnson & Johnson presented Phase 3 study results for ICOTYDE in treating plaque psoriasis, showing up to 70% skin clearance by Week 112. The drug, approved by the FDA in March 2026, also showed significant clearance in specific body areas. JNJ's stock closed at $258.66 on Thursday, up 0.47% in pre-market trading.

Johnson & Johnson (JNJ) presented two-year data from the Phase 3 ICONIC-TOTAL study, showing ICOTYDE® (icotrokinra) sustained skin clearance in high-impact plaque psoriasis. Key results: 60% scalp, 89% genital, and 63% hand/foot clearance at Week 112. Safety profile remained consistent. Data was shared at the EADV Congress 2026.

Johnson & Johnson (JNJ) reported two-year Phase 3 study results for ICOTYDE, showing significant skin clearance in patients with psoriasis in high-impact areas. The drug achieved 60% complete scalp clearance, 89% genital clearance, and 63% hand/foot clearance at Week 112. Overall clearance rates improved from 57% to 70% over the study period. The company noted consistent safety findings with no new signals.

Johnson & Johnson (JNJ) reported Phase 3 trial results for ICOTYDE, showing 70% of patients achieved clear or almost clear skin after 112 weeks. The treatment demonstrated effectiveness in difficult-to-treat areas and maintained its safety profile. The ICONIC-TOTAL study included adults and adolescents with moderate to severe plaque psoriasis.

Johnson & Johnson (JNJ) presented two-year data on IMAAVY for generalized myasthenia gravis, showing sustained disease control and safety in adolescents. The company also shared insights on adult treatment patterns. JNJ aims to address unmet needs in immune and neuromuscular disorders, with the data supporting its immunology strategy.

Johnson & Johnson (JNJ) presented new data on IMAAVY® for generalized myasthenia gravis (gMG) at the 2026 MGFA and AANEM meetings. Two-year results from a Phase 2/3 study showed sustained disease control in adolescents, with improvements in daily function and muscle strength, and reduced corticosteroid use. No new safety signals were identified. HCPs cited fluctuating symptom control as a key reason for transitioning to IMAAVY, with 73.2% of patients reporting significant improvement.